JP2007517059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517059A5 JP2007517059A5 JP2006547564A JP2006547564A JP2007517059A5 JP 2007517059 A5 JP2007517059 A5 JP 2007517059A5 JP 2006547564 A JP2006547564 A JP 2006547564A JP 2006547564 A JP2006547564 A JP 2006547564A JP 2007517059 A5 JP2007517059 A5 JP 2007517059A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- disorder
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 4
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 4
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940125683 antiemetic agent Drugs 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000002519 immonomodulatory effect Effects 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 206010034010 Parkinsonism Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010068100 Vascular parkinsonism Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000018731 motor weakness Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53386203P | 2003-12-30 | 2003-12-30 | |
| PCT/US2004/043924 WO2005065455A1 (en) | 2003-12-30 | 2004-12-27 | Immunomodulatory compounds for the treatment of central nervous system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517059A JP2007517059A (ja) | 2007-06-28 |
| JP2007517059A5 true JP2007517059A5 (enExample) | 2007-11-22 |
Family
ID=34748974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547564A Abandoned JP2007517059A (ja) | 2003-12-30 | 2004-12-27 | 中枢神経系障害治療用の免疫調節化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050143344A1 (enExample) |
| EP (1) | EP1705988A4 (enExample) |
| JP (1) | JP2007517059A (enExample) |
| KR (1) | KR20060128960A (enExample) |
| CN (1) | CN1921758A (enExample) |
| AU (1) | AU2004311420A1 (enExample) |
| BR (1) | BRPI0418270A (enExample) |
| CA (1) | CA2551520A1 (enExample) |
| IL (1) | IL176581A0 (enExample) |
| WO (1) | WO2005065455A1 (enExample) |
| ZA (1) | ZA200605475B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| CN1956718A (zh) * | 2004-03-22 | 2007-05-02 | 细胞基因公司 | 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法 |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| KR20070010184A (ko) * | 2004-04-23 | 2007-01-22 | 셀진 코포레이션 | 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물 |
| ZA200704890B (en) * | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| TW200819435A (en) * | 2006-09-15 | 2008-05-01 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| CN107445940A (zh) | 2006-09-26 | 2017-12-08 | 细胞基因公司 | 作为抗肿瘤剂的5‑取代的喹唑酮衍生物 |
| BRPI0817525A2 (pt) | 2007-09-26 | 2014-11-18 | Celgene Corp | Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio. |
| CA2704663A1 (en) * | 2007-11-08 | 2009-05-14 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
| WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
| EP3354646A1 (en) | 2008-10-29 | 2018-08-01 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| EP2396312A1 (en) | 2009-02-11 | 2011-12-21 | Celgene Corporation | Isotopologues of lenalidomide |
| SMT201700097T1 (it) | 2009-05-19 | 2017-03-08 | Celgene Corp | Formulazioni di 4-ammino-2-(2,6-diossopiperidin-3-il)isoindolin-1,3-dione |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| AU2010333767A1 (en) | 2009-12-22 | 2012-07-05 | Celgene Corporation | (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| AU2012205809B2 (en) | 2011-01-10 | 2015-09-10 | Amgen (Europe) GmbH | Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines |
| UA113512C2 (xx) | 2011-03-11 | 2017-02-10 | Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування | |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| PH12014500593A1 (en) | 2011-09-14 | 2019-09-02 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
| DK2797581T3 (da) | 2011-12-27 | 2020-07-20 | Amgen Europe Gmbh | Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion |
| WO2013122778A1 (en) * | 2012-02-15 | 2013-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9249093B2 (en) | 2012-04-20 | 2016-02-02 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| HRP20190398T1 (hr) | 2012-08-09 | 2019-05-17 | Celgene Corporation | Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida |
| WO2014066243A1 (en) | 2012-10-22 | 2014-05-01 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| WO2015108889A1 (en) | 2014-01-15 | 2015-07-23 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| CA3096404A1 (en) | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| JP2023534528A (ja) | 2020-07-20 | 2023-08-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5788200A (en) * | 1996-07-25 | 1998-08-04 | Jones; C. Reid | Hidden shelf support bracket |
| US5929117A (en) * | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
| DE69734290T2 (de) * | 1996-11-05 | 2006-07-06 | The Children's Medical Center Corp., Boston | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| US5739119A (en) * | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| FR2756737B1 (fr) * | 1996-12-05 | 1999-01-08 | Rhone Poulenc Rorer Sa | Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
| TR200101504T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
| US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| US6419934B1 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US20030113318A1 (en) * | 1999-02-24 | 2003-06-19 | Tobinick Edward Lewis | TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US20030185826A1 (en) * | 1999-02-24 | 2003-10-02 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
| CA2361806C (en) * | 1999-03-18 | 2012-03-13 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| EP1313460A2 (en) * | 1999-11-09 | 2003-05-28 | Darwin Discovery Limited | Therapeutic use and formulation of (-)-tramadol |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US20020022627A1 (en) * | 2000-03-31 | 2002-02-21 | Dannenberg Andrew J. | Inhibition of cyclooxygenase-2activity |
| US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| CA2430669C (en) * | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7320991B2 (en) * | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| CA2457319C (en) * | 2001-08-06 | 2011-07-05 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| SI1505973T1 (sl) * | 2002-05-17 | 2010-06-30 | Celgene Corp | Kombinacija za zdravljenje multiplega mieloma |
| AU2003204344A1 (en) * | 2002-05-23 | 2003-12-11 | Milder, Dan George | Compositions and methods for the treatment of autoimmune diseases and neurological disorders |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| NZ540028A (en) * | 2002-10-24 | 2009-07-31 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| AU2003287381B2 (en) * | 2002-10-31 | 2008-03-06 | Celgene Corporation | Composition for the treatment of macular degenration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050103142A1 (en) * | 2003-11-18 | 2005-05-19 | Hamilton Wayne J. | Low angle intersecting and skew axis face gear |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
-
2004
- 2004-12-23 US US11/022,075 patent/US20050143344A1/en not_active Abandoned
- 2004-12-27 WO PCT/US2004/043924 patent/WO2005065455A1/en not_active Ceased
- 2004-12-27 AU AU2004311420A patent/AU2004311420A1/en not_active Abandoned
- 2004-12-27 KR KR1020067015162A patent/KR20060128960A/ko not_active Ceased
- 2004-12-27 BR BRPI0418270-7A patent/BRPI0418270A/pt not_active IP Right Cessation
- 2004-12-27 CN CNA2004800422084A patent/CN1921758A/zh active Pending
- 2004-12-27 JP JP2006547564A patent/JP2007517059A/ja not_active Abandoned
- 2004-12-27 CA CA002551520A patent/CA2551520A1/en not_active Abandoned
- 2004-12-27 EP EP04815914A patent/EP1705988A4/en not_active Withdrawn
- 2004-12-27 ZA ZA200605475A patent/ZA200605475B/en unknown
-
2006
- 2006-06-27 IL IL176581A patent/IL176581A0/en unknown
-
2008
- 2008-05-23 US US12/154,575 patent/US20080227816A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517059A5 (enExample) | ||
| Pinna | Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued | |
| RU2489155C2 (ru) | Лечение нейродегенеративных заболеваний | |
| O’Hagan | Fluorine in health care: Organofluorine containing blockbuster drugs | |
| TWI494293B (zh) | 用於治療認知障礙之α-胺基醯胺衍生物 | |
| US20090036487A1 (en) | Combinations | |
| PT1107746E (pt) | Metodos para a utilizacao e composicoes que compreendem os inibidores da retoma da dopamina | |
| JP2017511339A5 (enExample) | ||
| WO2014052935A2 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| CA2670405A1 (en) | Combination treatments for alzheimer's disease and related neurodegenerative diseases | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| JP2005506308A5 (enExample) | ||
| EP1641461B1 (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| ZA200501311B (en) | Pyrrolidone derivatives as MAOB inhibitors | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| JP2019530674A5 (enExample) | ||
| JP2022512652A (ja) | Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療 | |
| CN114727989A (zh) | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 | |
| JP2005194263A (ja) | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 | |
| JP2022519541A (ja) | 不安関連障害を処置するための組成物および方法 | |
| JP2009515934A5 (enExample) | ||
| RU2003101396A (ru) | Замещенные нитрированные катехолы, их применение в лечении некоторых расстройств центральной и периферической нервной системы и содержащие их фармацевтические композиции | |
| Wiryana et al. | Low dose ketamin | |
| JP2006519875A5 (enExample) |